2 billion varieties of aspirin Who will be the first to declare consistency evaluation?

According to the China Cardiovascular Disease Report 2018, there are 290 million patients with cardiovascular disease in China, of whom 13 million are stroked, 11 million are coronary heart disease, 5 million are lung primary heart disease, 4.5 million are heart failure, 2.5 million are rheumatic heart disease, 2 million are congenital heart disease and 245 million are hypertensiveWith the development of aging population, as well as high blood pressure, high blood lipids, high blood sugar high-risk factors, formed a large anti-thrombosis drug marketaspirin market position is indestructible
meters net data show that in 2018 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal anti-thrombosis drug market reached 31.358 billion yuan, an increase of 19.46% year-on-yearIn 2018, China's end-user market for end-of-life aspirin intestinal tablets reached 2,298 million yuan, up 12.28% Year-on-YearChina's public medical institutions terminal anti thrombosis drug sales (units: million yuan)aspirin belongs to NSAIDs drugs, clinical use of very wide range of drugs, the use of very largeAspirin has different mechanisms of action, such as heat relief and analgesics, anti-rheumatic, and inhibition of platelet aggregation, respectively, according to the doseWith medical progress, at present, the anti-heat analgesic market compound preparations occupy 90% of the market, so aspirin is mainly used to inhibit platelet aggregationaspirin inhibits platelet activity by inhibiting COX, making serine acetylation at the center of COX molecular activity in platelets, blocking the synthesis of TXA2, while also making platelet protein acetylation, and inhibiting platelet membrane enzymes, thereby inhibiting platelet clottingIn clinical use in the treatment and prevention of cerebral infarction, myocardial infarction and other cardiovascular diseases commonly used by the daily 75 to 100 mgIn addition, foreign studies of aspirin have reduced the incidence of lung cancer in women, as well as the risk of dementia or disabilityinhibit edeplatelet accumulation aspirin market can not be underestimated
meters of internal network data show that in 2018, the domestic key provinces and cities of public hospitals aspirin intestinal tablet sedative sage drug market 267 million yuan, up 8.87 percent yoy, in the first half of 2019 aspirin intestinal tablet syllone drug market 127 million yuan, of which the original drug Bayer aspirin intestinal tablets (100 mg) accounted for 98.43 percent of the market share, domestic drug only 1.57 percentdomestic ownership of aspirin intestinal tabletproduction production approval of 237 enterprises, but used to inhibit platelet aggregation of dosage forms, specifications or is still not optimisticThe author believes that the imitation of aspirin intestinal tablets and the original aspirin intestinal tablets (100mg) compared with only 5 enterprises, respectively, stone medicine O'Yi pharmaceutical, Hebei Ruisen pharmaceutical, Shenyang Ogina pharmaceutical, Shanxi orchid medicine and Chenxin pharmaceutical industryIn addition, the aspirin intestinal solution used to inhibit platelet aggregation 75mg only stone medicine Oyi Pharmaceuticals, Sichuan Defeng Pharmaceuticals and Hainan Bikai Pharmaceuticals 3 holding production approvalis it difficult to evaluate the consistency of aspirin?according to the minet consistency evaluation database, as of now anti-thrombosis drugs through consistency evaluation products have sulphate chloropidogdo tablets, tigrelo tablets, apixaban tablets, saffarin sodium tablets and other 5 varieties, ZhengdaTianqing, stone medicine, Shenzhen Xinlitai in a leading position, have more than two products have been evaluatedstone medicine is intended to anti-thrombotic anti-coagulation has a certain basis for research and development, especially aspirin preparations have 7 batch numbers, respectively, aspirin intestinal tablets (100mg, 75mg, 50mg, 25mg, 300mg and aspirin c intestinal tablets), as well as compound aspirin tablets, become one of the most batch of aspirin preparations, whether to open the quality of the variety of evaluation breakthrough, highly attentionso far, aspirin has not yet been declared by enterprises to the consistency of generic drugs evaluationAspirin is a century-old drug, after many years of clinical treatment and safety has not been questioned, in the anti-platelet aggregation market has become more than 90% of the elderly known varietiesthe original drug Bayer's aspirin intestinal tablets (100mg x 30 tablets) only 15.70 yuan, the daily amount of 0.52 yuan of low-cost accounted for more than 90% of the domestic market shareDomestic small-dose drug price of about 0.1 yuan per day, in such a situation, invest millions of funds to do consistency evaluation is not worth it, according to the current low-cost winning bid, a number of mindless layout consistency evaluationon the other hand, according to the relevant research data, the determination of healthy young population subjects oral single-dose aspirin intestinal tablets and commercially available aspirin reference agents, absorption speed, absorption and relative bioavailability of the body has bioequivalence, and for the elderly group of subjects have a large rheijucityIn other words, unrated imitation aspirin intestinal tablets were less effective in antiplatelet aggregationTherefore, it has also led to the gap in the production process of aspirin intestinal tablets and the difficulty of consistency evaluation, which makes many enterprises discouragedHowever, through the technical attack will always have a breakthrough, look forward to eating crabs, change the current situation of greendata source: Rice Net Database